Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a daily zinc pill tame insulin resistance in polyendocrine ovarian syndrome?

NCT ID NCT07801001

Disease control Sponsor: Bangladesh Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This trial tests whether taking 50 mg of zinc daily for 12 weeks, alongside standard treatment, improves insulin resistance and other features of polyendocrine metabolic ovarian syndrome (PMOS) in women aged 18 to 45. PMOS is a common hormone condition linked to insulin resistance, which can lead to irregular periods, excess hair growth, and higher diabetes risk. Researchers will compare zinc against a placebo in 74 newly diagnosed women, measuring changes in insulin resistance, blood fats, oxidative stress, and symptoms like hirsutism and menstrual regularity.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Elemental zinc 50 mg taken orally once daily for 12 weeks
What this could lead to
If zinc helps, it could offer a safe, low-cost addition to standard care for improving insulin resistance and related symptoms in women with PMOS.
What could go wrong
This is a small, early-stage trial with 74 participants, so results may not apply broadly. Zinc can cause stomach upset, and the supplement may not outperform placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 74 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2027

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * the updated evidence based Rotterdam Criteria (revised 2023) * newly diagnosed women with PMOS * age above 18 years upto 45 years Exclusion Criteria: * Pregnancy and lactating mother. * diagnosed case of Diabetes mellitus, liver disease, kidney disease, cardiovascular disease * Any acute or chronic infective or inflammatory disease. * Patients receiving Zinc supplementation within the last three months. * Exclusion of PMOS mimicking disease include hyperprolactinemia, adrenal hyperandrogenism, ovarian hyperandrogenism, cushing syndrome, acromegaly etc. * Known allergy to Zinc supplementation. * Those who will not give informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Polycystic ovary syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Polyendocrine metabolic ovarian syndrome (PMOS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bangladesh Medical University

    Dhaka, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.